Inactive Instrument

Cubist Pharmaceuticals Inc Stock

Stocks

End-of-day quote Nasdaq Other stock markets
- ^USD	-

10/12/14	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
09/12/14	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE

10/12/14	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
09/12/14	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE
09/12/14	Merck : to take on superbugs with Cubist Pharma buy	RE
09/12/14	AstraZeneca : Merck to take on superbugs with Cubist Pharma buy	RE
09/12/14	Apple : S&P 500 posts worst day since Oct; energy shares sink	RE
08/12/14	Cubist Pharmaceuticals : options unusually active before Merck deal	RE
06/12/14	Cubist Pharmaceuticals : Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT	RE
21/05/13	Cubist Pharmaceuticals Inc : U.S. court ruling favors Cubist in patent case versus Hospira	RE

13/01/15	Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	BU
20/12/14	Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	BU
16/12/14	Cubist Pharmaceuticals : SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company	PR
13/12/14	Cubist Pharmaceuticals : SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	BU
12/12/14	Cubist Pharmaceuticals : CBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. in Connection With the Fairness of the Sale of the Company to Merck & Co.	BU

21/12/14	Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen
20/12/14	Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées
09/12/14	Merck : compte toujours acheter Cubist malgré un souci sur le Cubicin
08/12/14	Cubist Pharmaceuticals : Merck & Co acquiert Cubist Pharma pour 8,4 milliards de dollars
08/12/14	Cubist Pharmaceuticals : Wall Street ouvre en baisse, l'Asie inquiète

Manager	Title	Age	Since
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	01/01/1997

Director	Title	Age	Since
Martin Hermanus Soeters BRD	Director/Board Member	72	01/09/2006
Kenneth J. Martin BRD	Director/Board Member	72	25/09/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENERON PHARMACEUTICALS, INC.	+2.06%	+3.33%	+21.48%	-19.31%	63.09B
UCB	+0.74%	+3.73%	+53.05%	+208.91%	55.61B
SAMSUNG BIOLOGICS CO.,LTD.	-3.10%	+34.30%	+34.30%	+34.30%	41.64B
CSL LIMITED	-2.36%	+6.28%	-51.83%	-59.27%	38.98B
BIOGEN INC.	+6.97%	+8.17%	+70.21%	-23.28%	29.82B
MODERNA, INC.	+12.59%	+13.35%	+144.26%	-44.13%	23.71B
INCYTE CORPORATION	+5.78%	+9.73%	+60.64%	+80.73%	21.48B
INNOVENT BIOLOGICS, INC.	-1.25%	-1.31%	-8.80%	+146.80%	16.87B
SWEDISH ORPHAN BIOVITRUM AB	-0.81%	+5.91%	+68.18%	+121.16%	16.74B
Average	+2.25%	+3.29%	+43.50%	+49.55%	34.22B
Weighted average by Cap.	+1.77%	+3.29%	+37.42%	+45.51%

Employees

Sector